Pharmaceutical composition containing acylated insulin
By optimizing the components and pH value of acylated insulin formulations, the stability problem of insulin formulations has been solved, resulting in a longer shelf life and better efficacy, making them suitable for medical products.
WO2026109062A1PCT designated stage Publication Date: 2026-05-28GAN & LEE PHARM CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- GAN & LEE PHARM CO LTD
- Filing Date
- 2025-11-25
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Existing insulin formulations suffer from chemical and physical stability issues during storage and are not administered frequently enough to meet the demands for longer duration of action and better efficacy.
Method used
The formulation employs a pharmaceutical preparation containing acylated insulin, zinc ions, preservatives, tension modifiers, and a buffer solution. The buffer solution contains citric acid or citrate and has a pH of 6.5-8.5. The stability of the formulation is improved by optimizing the component ratio and pH value.
Benefits of technology
It achieves excellent chemical and physical stability of pharmaceutical preparations, extends shelf life, and improves efficacy, making it suitable for use as a medical product.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN2025137614_28052026_PF_FP_ABST
Abstract
Provided are an acylated insulin preparation, a pharmaceutical composition of acylated insulin and a long-acting GLP-1 compound, and the medical use thereof. The preparation and the pharmaceutical composition have satisfactory physical stability, chemical stability, and safety.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
CN115154591A
CN116789801A
CN118139875A
US20240374692A1
WO2021136303A1